Selecting the target population for new Alzheimer drugs: challenges and expectations

The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators

“…More specifically, we focused on novel immunotherapies aimed at amyloid β and tau, two relevant biomarkers. The commentaries to our paper2 3 acknowledge our conclusion: screening for AD involve ethical costs that cannot be justified unless a drug with clinically relevant effect (with acceptable safety) becomes available.…”